Drugs / Allogeneic NK
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06284226 | Mar 2022 → Jun 2025 | — | Beijing Kejing Biotechnology Co., Ltd. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06284226 ↗ |
| Modality | Cell therapy | “allogeneic natural killer cells” NCT06284226 ↗ |